Saracatinib-sensitive versus -resistant, PIK3CA mutant colorectal cancer xenografts
Summary:
Analysis of patient-derived colorectal cancer (CRC) xenografts with a PIK3CA mutation with enhanced sensitivity to Src inhibitor saracatinib. Dysregulation of Src and PI3K (phosphoinositide 3-kinase) signaling pathways is common in CRC. Results provide insight into CRC model response to saracatinib.
GPL6244:
[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version]
Citation:
Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM et al. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res 2012 May 1;18(9):2704-14. PMID: 22553375
